HC Wainwright & Co. Maintains Buy on Kezar Life Sciences, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Kezar Life Sciences (NASDAQ:KZR) and raises the price target from $18 to $20.
September 25, 2023 | 10:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kezar Life Sciences' price target has been raised from $18 to $20 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Kezar Life Sciences. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100